Nasdaq · CIK 0001833214
SABS SAB Biotherapeutics, Inc.
Insider trading from SEC Form 4. Last filing 24 d ago.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Signals
Open-market buys and sells at SAB Biotherapeutics, Inc., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 36 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | Alexandra Kropotova CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -473 | - | - | 41,853 | 24 d ago |
| Mar 24, 2026 | Alexandra Kropotova CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -988 | - | - | 43,296 | Mar 25, 2026 |
| Feb 3, 2026 | Christoph Lawrence Bausch CHIEF OPERATING OFFICER | AGrant or award Stock option (right to buy)derivative | +1,800,000 | $0.00 | $0 | 1,800,000 | Feb 5, 2026 |
| Feb 3, 2026 | Alexandra Kropotova CHIEF MEDICAL OFFICER | AGrant or award Stock option (right to buy)derivative | +2,400,000 | $0.00 | $0 | 2,400,000 | Feb 5, 2026 |
| Feb 3, 2026 | Samuel J Reich CEO | AGrant or award Stock option (right to buy)derivative | +4,800,000 | $0.00 | $0 | 4,800,000 | Feb 5, 2026 |
| Feb 3, 2026 | Lucy To See Remarks | AGrant or award Stock option (right to buy)derivative | +2,400,000 | $0.00 | $0 | 2,400,000 | Feb 5, 2026 |
| Feb 3, 2026 | Eddie Joe Sullivan PRESIDENT | AGrant or award Stock option (right to buy)derivative | +3,000,000 | $0.00 | $0 | 3,000,000 | Feb 5, 2026 |
| Jan 5, 2026 | Rita Jain director | AGrant or award Stock Option (right to buy)derivative | +240,000 | $0.00 | $0 | 240,000 | Jan 7, 2026 |
| Jan 5, 2026 | David Zaccardelli director | AGrant or award Stock Option (right to buy)derivative | +240,000 | $0.00 | $0 | 240,000 | Jan 7, 2026 |
| Dec 16, 2025 | Helen K. Ellias director | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 18, 2025 |
| Dec 16, 2025 | Scott Giberson director | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 18, 2025 |
| Dec 16, 2025 | David Link director | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 18, 2025 |
| Dec 16, 2025 | Erick Lucera director | AGrant or award Stock option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 18, 2025 |
| Dec 16, 2025 | William James Polvino director | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 18, 2025 |
| Dec 16, 2025 | Jay S Skyler director | AGrant or award Stock Option (right to buy)derivative | +150,000 | $0.00 | $0 | 150,000 | Dec 18, 2025 |
| Dec 11, 2025 | Alexandra Kropotova CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -988 | - | - | 44,284 | Dec 12, 2025 |
| Sep 29, 2025 | Sessa Capital (Master), L.P. director | MOption exercise Common Stock | +1,740,000 | $1.75 | $3.0M | 2,198,457 | Oct 1, 2025 |
| Sep 29, 2025 | Andrew Moin director | MOption exercise Common Stockindirect: See Footnote. | +1,740,000 | $1.75 | $3.0M | 2,198,457 | Oct 1, 2025 |
| Sep 29, 2025 | Sessa Capital (Master), L.P. director | MOption exercise Series B Convertible Preferred Stockderivative | -17,400 | - | - | 211,100 | Oct 1, 2025 |
| Sep 29, 2025 | Andrew Moin director | MOption exercise Series B Convertible Preferred Stockderivativeindirect: See Footnote. | -17,400 | - | - | 211,100 | Oct 1, 2025 |
| Sep 19, 2025 | Alexandra Kropotova CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -1,977 | - | - | 45,272 | Sep 22, 2025 |
| Aug 26, 2025 | Christoph Lawrence Bausch CHIEF OPERATING OFFICER | AGrant or award Stock Option (right to buy)derivative | +600,000 | $0.00 | $0 | 600,000 | Aug 28, 2025 |
| Aug 26, 2025 | Alexandra Kropotova CHIEF MEDICAL OFFICER | AGrant or award Stock Option (right to buy)derivative | +2,400,000 | $0.00 | $0 | 2,400,000 | Aug 28, 2025 |
| Aug 26, 2025 | Samuel J Reich CEO & EXECUTIVE CHAIRMAN | AGrant or award Stock Option (right to buy)derivative | +4,800,000 | $0.00 | $0 | 4,800,000 | Aug 28, 2025 |
| Aug 26, 2025 | Eddie Joe Sullivan PRESIDENT | AGrant or award Stock Option (right to buy)derivative | +3,000,000 | $0.00 | $0 | 3,000,000 | Aug 28, 2025 |
| Aug 26, 2025 | Lucy To See Remarks | AGrant or award Stock Option (right to buy)derivative | +1,200,000 | $0.00 | $0 | 1,200,000 | Aug 28, 2025 |
| Jul 22, 2025 | Andrew Moin director | AGrant or award Series B Convertible Preferred Stockderivativeindirect: See Footnote. | +228,500 | - | - | 228,500 | Jul 24, 2025 |
| Jul 22, 2025 | Sessa Capital (Master), L.P. director | AGrant or award Series B Convertible Preferred Stockderivative | +228,500 | - | - | 228,500 | Jul 24, 2025 |
| Jul 22, 2025 | Andrew Moin director | AGrant or award Warrants (right to buy)derivativeindirect: See Footnote. | +228,500 | - | - | 228,500 | Jul 24, 2025 |
| Jul 22, 2025 | Sessa Capital (Master), L.P. director | AGrant or award Warrants (right to buy)derivative | +228,500 | - | - | 228,500 | Jul 24, 2025 |
| Jul 22, 2025 | Andrew Moin director | AGrant or award Warrants (right to buy)derivativeindirect: See Footnote. | +114,250 | - | - | 114,250 | Jul 24, 2025 |
| Jul 22, 2025 | Sessa Capital (Master), L.P. director | AGrant or award Warrants (right to buy)derivative | +114,250 | - | - | 114,250 | Jul 24, 2025 |
| Mar 27, 2025 | Alexandra Kropotova CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -1,179 | - | - | 47,249 | Apr 1, 2025 |
| Dec 18, 2024 | Alexandra Kropotova CHIEF MEDICAL OFFICER | FTax withholding Common Stock | -9,072 | - | - | 48,428 | Dec 31, 2024 |
| Nov 1, 2024 | Helen K. Ellias director | AGrant or award Stock Option (right to buy)derivative | +20,000 | $0.00 | $0 | 20,000 | Nov 5, 2024 |
| Nov 1, 2024 | Helen K. Ellias director | AGrant or award Stock Option (right to buy)derivative | +35,000 | $0.00 | $0 | 35,000 | Nov 5, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Christoph Lawrence BauschCHIEF OPERATING OFFICER
- Helen K. Elliasdirector
- Scott Gibersondirector
- Rita Jaindirector
- Alexandra KropotovaCHIEF MEDICAL OFFICER
- David Linkdirector
- Erick Luceradirector, cfo, officer
- Andrew Moindirector
- William James Polvinodirector
- Samuel J ReichCEO
- Jay S Skylerdirector
- Sessa Capital (Master), L.P.director
- Eddie Joe SullivanPRESIDENT
- Lucy ToSee Remarks
- David Zaccardelliceo, president, officer, director
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.